Vertex Pharmaceuticals Highlights Catalyst-Rich Pipeline Beyond Cystic Fibrosis

Vertex Pharmaceuticals highlighted upcoming clinical, regulatory and commercial catalysts spanning renal disease, pain management, cystic fibrosis and endocrinology at a Wells Fargo healthcare conference. The update signals a potentially active pipeline and commercialization calendar, but disclosed no new trial data, financial guidance or specific catalyst timing.